Publications by authors named "Ahmed I Elbehiry"
Article Synopsis
- Alzheimer's disease is a major cause of dementia, especially in people over 60, with cases expected to rise significantly by 2050, highlighting the urgent need for effective treatments.
- Lecanemab, a monoclonal antibody that targets amyloid-beta plaques, has shown promise in slowing Alzheimer's progression, supported by positive clinical trial results and ongoing research to enhance understanding of its effects.
- A systematic review and meta-analysis of lecanemab at a dosage of 10 mg/kg revealed significant cognitive improvements in Alzheimer's patients, while also noting potential safety concerns that necessitate careful monitoring in clinical settings.
